These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 5609464)

  • 1. [Some indices of the blood coagulation system during treatment of ovarian and uterine cancer].
    Leush SS
    Pediatr Akus Ginekol; 1967; 3():55-6. PubMed ID: 5609464
    [No Abstract]   [Full Text] [Related]  

  • 2. [Change in the nonspecific reactivity of patients with neoplasia of the uterus and ovaries during treatment].
    Veksler IG; Legun OD; Struk VI
    Pediatr Akus Ginekol; 1969; 4():48-51. PubMed ID: 5364487
    [No Abstract]   [Full Text] [Related]  

  • 3. [State of the hemostasis system in patients with benign tumors of the uterus and adnexa uteri in pre- and postoperative periods].
    Savchenko VF
    Akush Ginekol (Mosk); 1983 Dec; (12):67-70. PubMed ID: 6666829
    [No Abstract]   [Full Text] [Related]  

  • 4. Association between blood rheology, thrombosis and cancer survival in patients with gynecologic malignancy.
    von Tempelhoff GF; Nieman F; Heilmann L; Hommel G
    Clin Hemorheol Microcirc; 2000; 22(2):107-30. PubMed ID: 10831062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. alpha-Fetoprotein as a biochemical marker in patients with gynecologic malignancy.
    Donaldson ES; van Nagell JR; Gay EC; Purcell S; Meeker WR; Kashmiri R; Hunter L; van de Voorde J
    Gynecol Oncol; 1979 Feb; 7(1):18-24. PubMed ID: 86481
    [No Abstract]   [Full Text] [Related]  

  • 6. [Blood serum protein study in oncological patients].
    Gutman EKh; Plaudé RK; Pirogova TF; Vorob'eva LF
    Vopr Onkol; 1978; 24(3):68-72. PubMed ID: 644967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The association of RCAS1 serum concentration with the reversibility or irreversibility of the process of immune cytotoxic activity restriction during normal menstrual cycle, cancer relapse, and surgical treatment for various types of squamous cell carcinomas and adenocarcinomas.
    Dutsch-Wicherek M; Wicherek L
    Am J Reprod Immunol; 2008 Mar; 59(3):266-75. PubMed ID: 18275520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early hemostatic disorders in patients with gynecologic tumors.
    Di Roberto P; Benedetti Panici P; Scambia G; Laghi F; Margariti PA; Mancuso S; Bompiani A
    Eur J Gynaecol Oncol; 1986; 7(2):109-12. PubMed ID: 2941303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Regulation of ceruloplasmin activity in oncogynecological diseases].
    Gusarova IuN; Stepanova EV; Landesman EO; Koroleva OV; Vavilova TP; Makarov OV; Kosetskiĭ VN
    Vopr Med Khim; 2002; 48(4):388-93. PubMed ID: 12506616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparative investigation of the determination of fibrinogen (author's transl)].
    Schander K; Schneider J; Ventocilla B
    Geburtshilfe Frauenheilkd; 1974 Sep; 34(9):763-6. PubMed ID: 4437566
    [No Abstract]   [Full Text] [Related]  

  • 11. [Special aspects of the leukocytes in various types of neoplasms of the uterus and ovary].
    Palagi R; Giorgi G; Bocci F
    Minerva Ginecol; 1970 Jan; 22(2):104-6. PubMed ID: 5446149
    [No Abstract]   [Full Text] [Related]  

  • 12. Gynecologic cancer: uterine and ovarian malignancies.
    Rubin D
    RN; 1987 Jun; 50(6):52-7. PubMed ID: 3647594
    [No Abstract]   [Full Text] [Related]  

  • 13. [Incidence of hemorrhagic complications and the system of hemostasis in endometriosis].
    Bromboszcz A; Blicharski J; Lisiewicz J; Liber Z
    Ginekol Pol; 1981 Sep; 52(9):819-23. PubMed ID: 7319281
    [No Abstract]   [Full Text] [Related]  

  • 14. [Alcoholization of the hypophysis in malignant utero-ovarian tumors].
    Greco T; Sbaragli F; Mininni D
    Osp Ital Chir; 1965 Apr; 12(4):419-23. PubMed ID: 5829314
    [No Abstract]   [Full Text] [Related]  

  • 15. [Study of the immunological blood-coagulation changes caused by radiotherapy in subjects with neoplasms].
    Di Lella V; D'Angelo F; Morucci M; Placanica A
    Nunt Radiol; 1968 Nov; 34(11):1403-15. PubMed ID: 5754438
    [No Abstract]   [Full Text] [Related]  

  • 16. [Changes in blood rheological properties in gynecologic tumors in the postoperative period].
    Karabanov GN; Nikov NP
    Vopr Onkol; 1983; 29(7):85-8. PubMed ID: 6880138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Serum erythropoietin concentration in women with uterine or ovarian tumors].
    Chudek J; Wiecek A; Kokot F; Grochal A; Switała J; Kanwiszer J
    Przegl Lek; 1998; 55(2):47-50. PubMed ID: 9695642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical features and outcomes of uterine and ovarian carcinosarcoma.
    Jonson AL; Bliss RL; Truskinovsky A; Judson P; Argenta P; Carson L; Dusenbery K; Downs LS
    Gynecol Oncol; 2006 Mar; 100(3):561-4. PubMed ID: 16271748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical markers in gynaecological cancer.
    Farrell RJ
    Ir Med J; 1980 Aug; 73(8):285-6. PubMed ID: 6161106
    [No Abstract]   [Full Text] [Related]  

  • 20. [Comparative study of total 17-ketosteroids and free 17-hydroxycorticosteroids in the plasma of women with carcinoma of the cervix, the uterus, or the ovary].
    Bénard H; Bourdin JS; Saracino R; Seeman A
    Rev Fr Etud Clin Biol; 1968 Nov; 13(9):853-9. PubMed ID: 5709510
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.